bh 3 has been researched along with Autoimmune Lymphoproliferative Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auer, F; Bis, AM; Borkhardt, A; Dujovny, T; Fischer, U; Ginzel, S; Gombert, M; Harlev, D; Keller, B; Koren, A; Levin, C; Miskin, H; Nabhani, S; Postovsky, S; Schipp, C; Stepensky, P; Warnatz, K | 1 |
1 other study(ies) available for bh 3 and Autoimmune Lymphoproliferative Syndrome
| Article | Year |
|---|---|
STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Topics: Apoptosis; Autoimmune Lymphoproliferative Syndrome; Biphenyl Compounds; Butylated Hydroxytoluene; Case-Control Studies; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Family; Fas Ligand Protein; fas Receptor; Female; Gene Expression Profiling; Germ-Line Mutation; Humans; Immunoblotting; Immunophenotyping; Leukocytes, Mononuclear; Lymphocytes; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; STAT3 Transcription Factor; Sulfonamides; T-Lymphocytes | 2017 |